Mammoth Biosciences

Mammoth owns arguably the most important asset in in-vivo gene editing: proof that you can edit tissues beyond the liver with a single AAV. Its NanoCas nuclease is roughly 425 amino acids — about one-third the size of Cas9 — small enough to co-package with a guide RNA into one AAV vector, and in 2025 the company published data (bioRxiv, presented at ASGCT) showing 10–40% dystrophin editing across quadricep, calf, and heart muscle in a humanized Duchenne mouse model and up to ~30% editing in the skeletal muscle of cynomolgus macaques. That directly attacks the delivery bottleneck that has confined most in-vivo CRISPR to the liver, and it validated the enzyme-discovery engine — 176 ultracompact systems screened from metagenomic data, then engineered — that also powers the DETECTR diagnostics franchise that earned an FDA EUA during COVID. The commercial model is capital-efficient: rather than funding its own clinical trials, Mammoth licenses enzymes, anchored by a 2024 Regeneron collaboration worth up to $100M upfront for AAV-delivered editing. Founded by Nobel laureate Jennifer Doudna with a $1B+ unicorn valuation and roughly $303M raised, Mammoth sits on a scientifically differentiated, partner-funded platform pointed at muscle and CNS diseases — the largest untapped markets in genetic medicine.

Mammoth's compact-enzyme lead is real but narrowing fast: extrahepatic delivery is the entire industry's obsession, and every well-capitalized editing company plus the AAV-engineering field is racing at the same target, so a size advantage measured in amino acids is a fragile moat against rivals with deeper balance sheets and clinical infrastructure. The NanoCas muscle data, while striking, is preclinical — non-human-primate editing percentages are not durability, safety, or efficacy in patients, and the path from a macaque quadricep to an approved Duchenne therapy is years of expensive, high-attrition trials that Mammoth does not run itself. That licensing-first model caps the upside: partners capture the therapeutic value while Mammoth collects milestones and royalties, and its last priced round was the September 2021 Series D — nearly five years without a fresh mark in a sector that has repriced venture biotech sharply lower. The diagnostics business never scaled into a durable franchise after the COVID EUA. Doudna's imprimatur and the unicorn label are prestige, not revenue, and a private company burning against a stale 2021 valuation eventually has to raise into a hostile market or prove its enzymes generate real royalty streams. Compact CRISPR is a genuine breakthrough; owning it commercially, as one licensor among many, is the harder problem.